Vibalogics to invest $150M in Boston virotherapy facility

By Sean Whooley | November 16, 2020

Vibalogics announced that it initiated the first phase of its planned $150 million investment in a virotherapy facility near Boston.

The global contract development and manufacturing organization (CDMO) has a three-year investment plan which includes building a 110,000 square-foot facility, with the $150 million covering redevelopment, equipment and personnel, according to a news release.

Get the full story at our sister site, MassDevice.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].